• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微生物群相关共代谢产物在代谢相关脂肪性肝病进展中的作用:一篇叙述性综述

The Role of Microbiota-Related Co-Metabolites in MASLD Progression: A Narrative Review.

作者信息

Martin-Grau Maria, Monleón Daniel

机构信息

Department of Pathology, University of Valencia, 46010 Valencia, Spain.

University Clinical Hospital of Valencia Research Foundation (INCLIVA), 46010 Valencia, Spain.

出版信息

Curr Issues Mol Biol. 2024 Jun 25;46(7):6377-6389. doi: 10.3390/cimb46070381.

DOI:10.3390/cimb46070381
PMID:39057023
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11276081/
Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a growing health concern due to its increasing prevalence worldwide. Metabolic homeostasis encompasses the stable internal conditions vital for efficient metabolism. This equilibrium extends to the intestinal microbiota, whose metabolic activities profoundly influence overall metabolic balance and organ health. The metabolites derived from the gut microbiota metabolism can be defined as microbiota-related co-metabolites. They serve as mediators between the gut microbiota and the host, influencing various physiological processes. The recent redefinition of the term MASLD has highlighted the metabolic dysfunction that characterize the disease. Metabolic dysfunction encompasses a spectrum of abnormalities, including impaired glucose regulation, dyslipidemia, mitochondrial dysfunction, inflammation, and accumulation of toxic byproducts. In addition, MASLD progression has been linked to dysregulation in the gut microbiota and associated co-metabolites. Short-chain fatty acids (SCFAs), hippurate, indole derivatives, branched-chain amino acids (BCAAs), and bile acids (BAs) are among the key co-metabolites implicated in MASLD progression. In this review, we will unravel the relationship between the microbiota-related metabolites which have been associated with MASLD and that could play an important role for developing effective therapeutic interventions for MASLD and related metabolic disorders.

摘要

代谢功能障碍相关脂肪性肝病(MASLD)因其在全球范围内的患病率不断上升,已成为一个日益严重的健康问题。代谢稳态包括对高效代谢至关重要的稳定内部条件。这种平衡延伸到肠道微生物群,其代谢活动深刻影响整体代谢平衡和器官健康。源自肠道微生物群代谢的代谢产物可被定义为微生物群相关的共代谢产物。它们充当肠道微生物群与宿主之间的介质,影响各种生理过程。最近对MASLD这一术语的重新定义突出了该疾病所特有的代谢功能障碍。代谢功能障碍包括一系列异常,包括葡萄糖调节受损、血脂异常、线粒体功能障碍、炎症以及有毒副产物的积累。此外,MASLD的进展与肠道微生物群和相关共代谢产物的失调有关。短链脂肪酸(SCFAs)、马尿酸盐、吲哚衍生物、支链氨基酸(BCAAs)和胆汁酸(BAs)是与MASLD进展相关的关键共代谢产物。在本综述中,我们将阐明与MASLD相关且可能在开发针对MASLD及相关代谢紊乱的有效治疗干预措施中发挥重要作用的微生物群相关代谢产物之间的关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8e/11276081/442ffd93443d/cimb-46-00381-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8e/11276081/e060e2cdeb90/cimb-46-00381-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8e/11276081/c0cbf3ac9c67/cimb-46-00381-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8e/11276081/442ffd93443d/cimb-46-00381-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8e/11276081/e060e2cdeb90/cimb-46-00381-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8e/11276081/c0cbf3ac9c67/cimb-46-00381-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8e/11276081/442ffd93443d/cimb-46-00381-g003.jpg

相似文献

1
The Role of Microbiota-Related Co-Metabolites in MASLD Progression: A Narrative Review.微生物群相关共代谢产物在代谢相关脂肪性肝病进展中的作用:一篇叙述性综述
Curr Issues Mol Biol. 2024 Jun 25;46(7):6377-6389. doi: 10.3390/cimb46070381.
2
Bioactive metabolites: A clue to the link between MASLD and CKD?生物活性代谢产物:非酒精性脂肪性肝病与慢性肾脏病之间联系的线索?
Clin Mol Hepatol. 2025 Jan;31(1):56-73. doi: 10.3350/cmh.2024.0782. Epub 2024 Oct 21.
3
NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.NAD代谢疗法在代谢功能障碍相关脂肪性肝病中的作用:肠道微生物群的潜在作用
iScience. 2024 Feb 9;27(3):109174. doi: 10.1016/j.isci.2024.109174. eCollection 2024 Mar 15.
4
Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment.MASLD 中的肠道微生物代谢产物:线粒体功能障碍在发病机制和治疗中的意义。
Hepatol Commun. 2024 Jul 5;8(7). doi: 10.1097/HC9.0000000000000484. eCollection 2024 Jul 1.
5
Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.膳食燕麦β-葡聚糖对微生物群的调节作用可预防脂肪性肝病进展。
JHEP Rep. 2024 Jan 3;6(3):100987. doi: 10.1016/j.jhepr.2023.100987. eCollection 2024 Mar.
6
Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.肠道微生物群、宿主基因和表观遗传修饰在代谢相关脂肪性肝病及代谢相关脂肪性肝病相关肝细胞癌中的相互作用
Gut. 2024 Dec 10;74(1):141-152. doi: 10.1136/gutjnl-2024-332398.
7
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation.肠道微生物衍生的吲哚化合物通过改善脂肪代谢和炎症缓解代谢功能障碍相关的脂肪性肝病。
Gut Microbes. 2024 Jan-Dec;16(1):2307568. doi: 10.1080/19490976.2024.2307568. Epub 2024 Feb 1.
8
Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).打破障碍:肠道内稳态在代谢相关脂肪性肝病(MASLD)中的作用。
Gut Microbes. 2024 Jan-Dec;16(1):2331460. doi: 10.1080/19490976.2024.2331460. Epub 2024 Mar 21.
9
Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction-associated steatotic liver disease: a comprehensive review.白细胞介素1受体1、肠道微生物群和胆汁酸在代谢功能障碍相关脂肪性肝病中的相互作用:综述
J Gastroenterol Hepatol. 2025 Jan;40(1):33-40. doi: 10.1111/jgh.16750. Epub 2024 Sep 29.
10
Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics.代谢相关脂肪性肝病(MASLD)防治的健康功能性食品生物标志物:网络药理学、肠道微生物群和多组学的综合分析
Nutrients. 2024 Sep 11;16(18):3061. doi: 10.3390/nu16183061.

引用本文的文献

1
Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis.代谢功能障碍相关脂肪性肝病与心房颤动:发病机制综述
World J Cardiol. 2025 Jun 26;17(6):106147. doi: 10.4330/wjc.v17.i6.106147.
2
Evaluation of Defensins as Markers of Gut Microbiota Disturbances in Children with Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).评估防御素作为肥胖和代谢功能障碍相关脂肪性肝病(MASLD)儿童肠道微生物群紊乱标志物的作用。
J Clin Med. 2025 May 16;14(10):3505. doi: 10.3390/jcm14103505.
3
Editorial for Special Issue: "Molecular Mechanisms Underlying Fatty Liver Disease: From Pathogenesis to Treatment".

本文引用的文献

1
Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.微生物群和免疫系统在代谢功能障碍相关脂肪性肝病发生和进展中的作用。
Nutrients. 2024 May 29;16(11):1668. doi: 10.3390/nu16111668.
2
Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).代谢功能障碍相关脂肪性肝病(MASLD)患者肝损伤进展过程中肠道微生物群组成的改变
Int J Mol Sci. 2024 Apr 16;25(8):4387. doi: 10.3390/ijms25084387.
3
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation.
特刊社论:“脂肪肝疾病的分子机制:从发病机制到治疗”
Curr Issues Mol Biol. 2025 Feb 27;47(3):160. doi: 10.3390/cimb47030160.
4
Microbiota Co-Metabolism Alterations Precede Changes in the Host Metabolism in the Early Stages of Diet-Induced MASLD in Wistar Rats.在饮食诱导的Wistar大鼠代谢相关脂肪性肝病(MASLD)早期阶段,微生物群共代谢改变先于宿主代谢变化。
Int J Mol Sci. 2025 Feb 2;26(3):1288. doi: 10.3390/ijms26031288.
肠道微生物衍生的吲哚化合物通过改善脂肪代谢和炎症缓解代谢功能障碍相关的脂肪性肝病。
Gut Microbes. 2024 Jan-Dec;16(1):2307568. doi: 10.1080/19490976.2024.2307568. Epub 2024 Feb 1.
4
Novel insights into metabolic-associated steatotic liver disease preclinical models.代谢相关性脂肪性肝病临床前模型的新见解。
Liver Int. 2024 Mar;44(3):644-662. doi: 10.1111/liv.15830. Epub 2024 Jan 30.
5
Short-chain fatty acids in diseases.短链脂肪酸与疾病
Cell Commun Signal. 2023 Aug 18;21(1):212. doi: 10.1186/s12964-023-01219-9.
6
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
7
The gut-liver axis and gut microbiota in health and liver disease.肠-肝轴与肠道微生物群在健康与肝病中的作用
Nat Rev Microbiol. 2023 Nov;21(11):719-733. doi: 10.1038/s41579-023-00904-3. Epub 2023 Jun 14.
8
Integrated Gut Microbiota and Urine Metabolite Analyses of T2DM with NAFLD Rat Model.基于非酒精性脂肪性肝病(NAFLD)大鼠模型的 2 型糖尿病(T2DM)肠道微生物群和尿液代谢物的综合分析。
Appl Biochem Biotechnol. 2023 Nov;195(11):6478-6494. doi: 10.1007/s12010-023-04419-8. Epub 2023 Mar 4.
9
Mediterranean Diet: The Role of Phenolic Compounds from Aromatic Plant Foods.地中海饮食:芳香植物性食物中酚类化合物的作用
Foods. 2023 Feb 16;12(4):840. doi: 10.3390/foods12040840.
10
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的全球流行病学:系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.